Adenosine triphosphate-binding pocket inhibitor for mixed lineage kinase domain-like protein attenuated alcoholic liver disease via necroptosis-independent pathway

Figure 4 Mixed lineage kinase domain-like protein adenosine triphosphate-binding inhibitor cannot evade cell death after necroptosis stimuli but inhibition of inflammation. A: U937, HT29 and FADD cells treated with Mixed lineage kinase domain-like protein (MLKL) adenosine triphosphate (ATP)-binding inhibitor (Compound-4) to determine cell viability; B: After induction of necroptosis in RAW 264.7 cells, MLKL ATP-binding inhibitor was administered to measure CXCL1, CXCL2, ICAM, and VCAM mRNA expression levels via quantitative real-time polymerase chain reaction; C and D: Western blot analysis of phosphorylated-nuclear factor kappa-B, nuclear factor kappa-B, phospho-c-Jun, c-Jun, I-kappa-B-alpha, phospho-I-kappa-B-alpha, c-Jun N-terminal kinases and phospho-c-Jun N-terminal kinases protein expression in RAW 264.7 cells after compound-4 treatment. ^aP < 0.05. ^bP < 0.01. ^cP < 0.001. ^dP < 0.0001. GAPDH: Glyceraldehyde 3-phosphate dehydrogenase; CPD4: Compound-4; EtOH: Ethyl alcohol.